Drugs / efdamrofusp alfa
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04370379 | May 2020 → Apr 2021 | wet macular degeneration | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03814291 | Apr 2019 → Mar 2020 | wet macular degeneration | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | efdamrofusp alfa | “This study reports the preclinical assessment and phase 1 clinical outcomes of a bispecific fusion protein, efdamrofusp alfa (code: IBI302), which is capable of neutralizing...” PMID 35648811 ↗ Jun 20221“The first 9 patients were randomized 2:1 to intravitreally receive efdamrofusp alfa 2 mg at weeks 0, 4, and 8 or aflibercept 2 mg at weeks 0, 4, 8, and 16.” PMID 36410472 ↗ Nov 2022 |
| Known as | IBI302 | “This study reports the preclinical assessment and phase 1 clinical outcomes of a bispecific fusion protein, efdamrofusp alfa (code: IBI302), which is capable of neutralizing...” PMID 35648811 ↗ Jun 2022 |
| Action | Inhibit | “which is capable of neutralizing both VEGF isoforms and C3b/C4b” PMID 35648811 ↗ Jun 2022 |
| Modality | Protein / enzyme biologic | “a bispecific fusion protein” PMID 35648811 ↗ Jun 2022 |
| Route | Intravitreal | “Intravitreal efdamrofusp alfa” PMID 35648811 ↗ Jun 2022 |